Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results

J Exp Clin Cancer Res. 2008 Jun 10;27(1):10. doi: 10.1186/1756-9966-27-10.

Abstract

Although some clinical and radiological features may predict malignancy presence in intraductal papillary mucinous pancreas neoplasms, preoperative diagnosis remains difficult. In this study we present 7 patients with Intraductal Papillary Mucinous Neoplasm (IPMN) studied both with 18FDG-PET and magnetic resonance cholangiopancreatography (MRCP). A focal hypermetabolism was documented in 2 patients (the standardized uptake value in the neoplastic foci was 6.7 and 9), while absence of FDG uptake in the neoplasm area was recorded in the remaining 5 cases. Mean follow-up was 27 months (range 21-34). The final judgement was benign IPMN in 5 cases and malignant IPMN in 2. PET scan always correctly predicted the presence or absence of malignancy, while MRCP failed to detect malignancy in 3/7 cases. In conclusion, this preliminary experience suggests that 18FDG-PET may prove useful for malignancy detection in IPMN, improving differential diagnosis with benign intraductal papillary growth by functional data.

MeSH terms

  • Adenocarcinoma, Mucinous / diagnosis
  • Adenocarcinoma, Mucinous / diagnostic imaging*
  • Adenocarcinoma, Mucinous / pathology
  • Carcinoma, Pancreatic Ductal / diagnosis
  • Carcinoma, Pancreatic Ductal / diagnostic imaging*
  • Carcinoma, Pancreatic Ductal / pathology
  • Carcinoma, Papillary / diagnosis
  • Carcinoma, Papillary / diagnostic imaging
  • Carcinoma, Papillary / pathology
  • Fluorodeoxyglucose F18* / metabolism
  • Follow-Up Studies
  • Humans
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / diagnostic imaging*
  • Pancreatic Neoplasms / pathology
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals* / metabolism

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18